RBC sales increase
This article was originally published in The Tan Sheet
Executive SummaryFirst-quarter net sales for RBC Life Sciences increased 18 percent to $6.35 million, the Irving, Texas-based firm announces May 5. Net earnings for the January-March period increased 9 percent to $355,000 compared to $325,000 last year, nutritional supplements manufacturer says. The firm, which specializes in introducing nanotechnology into nutritional and personal care products, says its nutritional segment grew more than 14 percent compared to the year-ago quarter due to an increase in revenues from its international licensees...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.